Bigot Frédéric, Bonnet Clément, Massard Christophe
University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department and Department of Medical Oncology, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
University of Paris Sud, Gustave-Roussy Cancer Campus, Drug Development Department and Department of Medical Oncology, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
Bull Cancer. 2017 Apr;104(4):370-379. doi: 10.1016/j.bulcan.2017.01.009. Epub 2017 Feb 23.
Management of genitourinary (GU) cancers is improving rapidly with the development of immunotherapy agents, especially anti-PD-1/anti-PD-L1 therapies. Large studies have shown better outcomes for the treatment of these patients, leading to new drug approvals and recent changes in standards of care in renal, prostate and bladder cancer. We performed a review of recent studies assessing efficacy of immuno-oncology therapies in GU cancers. New results are summarized and next ways of development of clinical research are discussed as the use of such therapies will soon be assessed in first-line or adjuvant settings.
随着免疫治疗药物的发展，尤其是抗PD-1/抗PD-L1疗法的出现，泌尿生殖系统（GU）癌症的管理正在迅速改善。大型研究表明，这些患者的治疗效果更好，这导致了新药获批以及近期肾癌、前列腺癌和膀胱癌护理标准的变化。我们对近期评估免疫肿瘤疗法在GU癌症中疗效的研究进行了综述。总结了新的研究结果，并讨论了临床研究的下一步发展方向，因为此类疗法很快将在一线或辅助治疗中进行评估。
